Moreover, the finding that indicated increased IL-6 concentration in the cholangiocellular carcinoma group is consistent with the findings of the studies which reported that IL-6 may be used as a marker of cholangiocellular carcinoma and IL-6 can be used in anticancer chemotherapy [17, 18]. This evidence concerns the gene IL6 and cholangiocarcinoma.